Predictor | Number of cancer deaths (%) for follow-up period (total 6023 deaths out of 46,779 cases) | aHR death from cancer (95% confidence limits) |
---|---|---|
Country of birth | Australia (ref.) n = 4129 (13.6) | 1.000 |
China (mainland) n = 73 (7.0) | 0.597 (0.467,0.762) | |
Germany n = 70 (16.3) | 0.957 (0.743,1.232) | |
Greece n = 66 (13.1) | 0.634 (0.491,0.820) | |
Italy n = 125 (17.1) | 0.795 (0.652,0.970) | |
Lebanon n = 71 (12.0) | 0.869 (0.681,1.108) | |
New Zealand n = 101 (10.0) | 0.922 (0.745,1.140) | |
Philippines n = 54 (7.0) | 0.698 (0.540,0.902) | |
United King. n = 460 (13.9) | 0.880 (0.783,0.991) | |
Vietnam n = 25 (5.2) | 0.469 (0.282,0.780) | |
Other mainly English- speaking n = 87 (10.4) | 1.013 (0.810,1.268) | |
Other mainly non-English speaking n = 762 (11.3) | 0.787 (0.720,0.859) | |
Age at diagnosis (18 to 80+ years) | Continuous n = 6023 (12.9) | 1.066 (1.063,1.070) |
SEIFA SES Disadvantage | 1 (most) (ref.) n = 1419 (17.0) | 1.000 |
2 n = 1335 (15.5) | 0.946 (0.866,1.034) | |
3 n = 1158 (13.1) | 0.895 (0.820,0.977) | |
4 n = 1143 (11.7) | 0.835 (0.764,0.912) | |
5 (least) n = 968 (8.6) | 0.684 (0.624,0.750) | |
Year of diagnosis (2003 to 2016) | Continuous (2013–16) n = 6023 (12.9) | 0.964 (0.957,0.972) |
Stage (degree of spread) | Local (ref.) n = 1565 (6.2) | 1.000 |
Regional n = 2747 (14.8) | 2.921 (2.739,3.115) | |
Distant n = 1711 (54.9) | 7.115 (6.485,7.807) | |
Comorbidity Index (Charlson) | 0 (ref.) n = 5392 (11.9) | 1.000 |
> 0 n = 631 (48.8) | 1.958 (1.727,2.219) | |
Treatment received (1st round) | Surgery n = 4167 (9.5) | 0.285 (0.263,0.308) |
Radiotherapy n = 2779 (8.9) | 0.768 (0.724,0.814) | |
Systemic n = 4778 (12.2) | 0.649 (0.60,0.702) |